eTheRNA immunotherapies NV is a clinical-stage company delivering innovative cancer immunotherapies from its proprietary mRNA-based TriMix platform. eTheRNA’s goal is to commercialize these immunotherapies to deliver long lasting clinical remission to cancer patients. eTheRNA was established in January 2013 as a spin-off from the VUB university in Belgium
eTheRNA was established in January 2013 as a spin-off company from the ‘Vrije Universiteit Brussel’ (VUB), following the development of its TriMix mRNA technology.
Contact information:
eTheRNA’s TriMix contains three naked mRNA molecules that combined work as a potent T-cell vaccine adjuvant:
TriMix is unique in the way it uses these three mRNA molecules to induce the proliferation of T-cells into either mature helper T-cells or cytotoxic T-cells – the ultimate ‘soldiers’ of the immune system that fight cancer cells and infectious agents. By combining TriMix with tumor-specific antigens or neoantigens the patient’s dendritic cells are stimulated to produce a more potent and larger population of antigen specific cytotoxic and helper T-cells compared to tumor antigens alone.
eTheRNA LNPs for intravenous delivery of mRNA have been show to exert first-in-class immune T-cell-specific responses in preclinical experiments. The induced immune responses are multifunctional and boostable. These premium results was achieved by optimizing the composition of the LNPs and designing them to target the spleen and not mainly the liver.
eTheRNA distinguishes itself from competitors on different levels:
Galileilaan 19, 2845 Niel, Belgium
+32 3 369 17 40
© 2020 Etherna | Studio Hanswijk
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.